Newsletter Subscription

Enter Name and Email

01 February 2012 - The Michael J. Fox Foundation awards research grant to Neurolixis

Adrian Newman-Tancredi Ph.D. has been named Principal Investigator of a two year research project funded by The Michael J. Fox Foundation and entitled "Enhanced activity in rodent models of Parkinsonism and L-DOPA-induced dyskinesia by preferential targeting of sub-populations of 5-HT1A receptors".

The project will be conducted as part of the activities of Neurolixis, a biopharmaceutical venture co-founded by Adrian and in which he serves as Chief Scientific Officer.

The project will use pre-clinical models to examine the effects of novel, highly selective and efficacious "biased agonists" targeting sub-populations of 5-HT1A receptors in those brain regions relevant to therapeutic properties. If the results of this study are promising, subsequent studies conducted by Neurolixis will aim to take novel drugs into preclinical and clinical development.

The Michael J. Fox Foundation description of the project can be found here.